Medicare Advantage Open Enrollment Period (OEP)

The Medicare Advantage Open Enrollment Period (OEP) is a period during which Medicare beneficiaries who are enrolled in a Medicare Advantage Plan can make changes to their coverage. It occurs annually from January 1 to March 31.

During the OEP, beneficiaries who are enrolled in a Medicare Advantage Plan can make the following changes to their coverage:

• Switch to a different Medicare Advantage Plan: Beneficiaries can switch to a different Medicare Advantage Plan that has a 5-star rating or enroll in a different Medicare Advantage Plan that is available in their service area.

• Drop their Medicare Advantage Plan and return to Original Medicare: Beneficiaries can also drop their Medicare Advantage Plan and return to Original Medicare. They can also enroll in a standalone Medicare Part D prescription drug plan.

It's important to note that the OEP is different from the Annual Enrollment Period (AEP), which occurs from October 15 to December 7 each year. During the AEP, beneficiaries can switch from Original Medicare to a Medicare Advantage Plan, switch from one Medicare Advantage Plan to another, or enroll in a Medicare Part D prescription drug plan.

Also, not all beneficiaries are eligible for the OEP. Those who are already enrolled in Original Medicare with a standalone Medicare Part D prescription drug plan are not eligible. The OEP is only available to those who are enrolled in a Medicare Advantage Plan.

Next Up

According to Mployer Insights’ 2026 analysis of 76,000+ employer benefit plans, disability insurance remains a major market differentiator, with only 41% of U.S. employers offering short-term disability (STD) and 38% offering long-term disability (LTD). While 60% salary replacement serves as the national standard across both benefit types, standard plan designs disproportionately expose higher earners due to median benefit caps of $1,602/week for STD and $8,273/month for LTD. Furthermore, alignment between STD benefit durations (median 26 weeks) and LTD elimination periods (68% at 90 days) remains a critical area for plan structure optimization.
Welcome to our latest release. We are excited for you to try the new features.
According to Mployer Insights’ 2026 analysis of 50,000+ employer health plans, prescription drugs account for over 25% of total benefit expenses, with Tier 4 specialty drugs driving the majority of high-cost claims. While Tier 4 copays average $123 with coinsurance requirements in 31% of plans, individual oncology therapies like Darzalex Faspro ($170,800/yr) and Keytruda ($158,200/yr) frequently exceed average individual stop-loss deductibles ($141,938). To mitigate exposure, self-funded employers are increasingly turning to independent, transparent PBM models and biosimilar substitution—which yields up to a 73% net cost reduction per patient.